No Evidence for Short-Term Regulation of Plasminogen Activator Inhibitor Activity by Insulin in Man

 

PDF Download Buy Article Permissions and Reprints

Summary

In crossectional studies a positive correlation has been found between circulating insulin, triglycerides and plasminogen activator inhibitor (PAI-1) activity. To directly examine the effect of insulin on PAI-1 activity in vivo, we determined the response of PAI-1 activity in 17 normal subjects to acute hyperinsulinemia (serum free insulin 92 ± 8 mU/l) during maintenance of normoglycemia (plasma glucose 5.1 ± 0.1 mmol/l). In 12 matched control subjects PAI-1 activity was measured during infusion of saline (serum free insulin 3.6 ± 0.3 mU/l, plasma glucose 5.2 ± 0.1 mmol/l). Plasma PAI-1 activity decreased during the insulin infusion from 9.0 α 1.4 to 5.6 α 0.8 U/ml (p <0.01), and during saline infusion from 7.0 ± 1.4 to 4.3 ± 0.6 U/ml (p <0.05). Serum triglyceride concentrations decreased from 1.09 ± 0.20 to 0.76 ± 0.09 mmol/l (p < 0.001) during hyperinsulinemia but remained unchanged during the saline infusion (1.04 ± 0.11 vs. 1.02 ± 0.12 mmol/l, NS). We conclude that insulin does not acutely change plasma PAI-1 activity, and that acute insulin-induced changes in serum triglycerides occur independently from those of PAI-1 activity.

• References

• 1 Kruithof EKO, Tran-Thang C, Bachmann F. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemostas 1986; 55: 65-69
  PubMedGoogle Scholar
• 2 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 25: 1557-1563
  PubMedGoogle Scholar
• 3 Landin K, Tengbom L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273-278
  CrossrefPubMedGoogle Scholar
• 4 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35 (03) 250-253
  CrossrefPubMedGoogle Scholar
• 5 Auwerx J, Bouillon R, Collen D, Gebores J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8 (01) 68-72
  CrossrefPubMedGoogle Scholar
• 6 Ferrannini E, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J Cardiovasc Pharmacol 1990; 15 (Supp) (15) S18-S25
  CrossrefPubMedGoogle Scholar
• 7 Modan M, Halkin H, Almong S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia, a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817
  CrossrefPubMedGoogle Scholar
• 8 Nikkilä E, Vesenne R, Miettinen T, Pelkonen R. Plasma-insulin in coronary heart-disease. Lancet 1965; 2: 508-511
  PubMedGoogle Scholar
• 9 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-494
  PubMedGoogle Scholar
• 10 Kooistra T, Bosma PJ, Tons HA, van den Berg AP, Meyer P, Princen HM. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989; 62: 723-728
  PubMedGoogle Scholar
• 11 Landin K, Tengbom L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemostas 1991; >65 (02) 130-133
  PubMedGoogle Scholar
• 12 Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F. Shortterm infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sei 1990; 79: 513-516
  PubMedGoogle Scholar
• 13 Potter van Loon BJ, de Bart ACW, Radder JK, Frölich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; 4 (Supp) (12) 93-94
  PubMedGoogle Scholar
• 14 Andreotti F, Davies GJ, Hackett D, Khan MI, de Bart A. Dooi-jewaard G, Maseri A, Kluft C. Cicardian variation of fibrinolytic factors in normal human plasma. Fibrinolysis 1988; 2 (Supp) (12) 90-92
  PubMedGoogle Scholar
• 15 Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemostas 1988; 59: 329-332
  PubMedGoogle Scholar
• 16 Kluft C, Andreotti F. Consequences of the cicardian fluctuation in plasminogen activator inhibitor 1 (PAI-1) for studies on blood fibrinolysis. Fibrinolysis 1988; 2 (Supp) (12) 93-95
  PubMedGoogle Scholar
• 17 Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-106
  CrossrefPubMedGoogle Scholar
• 18 Takada A, Takada Y, Urano T, Sakakibara K, Rydzewski A. Fluctuations of euglobulin lysis time, tissue plasminogen activator, and free and total plasminogen activator inhibitor levels in plasma daytime. Thromb Res 1990; 57: 13-20
  CrossrefPubMedGoogle Scholar
• 19 Chandler WL, Momin D, Whitten RO, Angleton P, Farin FM, Fritsche TR, Veith RC, Stratton JR. Insulin, cortisol and catecholamines do not regulate cicardian variation in fibrinolytic activity. Thromb Res 1990; 58: 1-12
  CrossrefPubMedGoogle Scholar
• 20 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23
  PubMedGoogle Scholar
• 21 Yki-Järvinen H, Young AA, Lamkin C, Foley JE. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest 1987; 79: 1713-1719
  CrossrefPubMedGoogle Scholar
• 22 Kadish AH, Little RL, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 1968; 14: 116-131
  PubMedGoogle Scholar
• 23 Gennaro WD, Van Norman JD. Quantitation of free, total and antibody-bound insulin in insulin treated diabetics. Clin Chem 1975; 21: 873-879
  PubMedGoogle Scholar
• 24 Wahlefeld AW. Triglyceride determination after enzymatic hydrolysis. In: Methods of Enzymatic Analysis. Bermeyer HV. (ed). Academic Press; New York: 2nd ed. 1974. pp 1831-1835
  Google Scholar
• 25 Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 1977; 26: 22-29
  CrossrefPubMedGoogle Scholar
• 26 Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-141
  CrossrefPubMedGoogle Scholar
• 27 Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-160
  CrossrefPubMedGoogle Scholar
• 28 Ducimetiere P, Eschwege R, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-210
  CrossrefPubMedGoogle Scholar
• 29 Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis 1989; 9: 362-367
  CrossrefPubMedGoogle Scholar
• 30 Kelley D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sorensen J, Berger M, Sonksen P, Gerich J. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest 1988; 81: 1563-1571
  CrossrefPubMedGoogle Scholar
• 31 Sundell BI, Nilsson TK, Hallmans G, Hellsten G, Dahlen G. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 1989; 80: 9-16
  CrossrefPubMedGoogle Scholar
• 32 Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of the hemostatic factors in regulation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator and type 1 plasminogen activator inhibitor. Arteriosclerosis 1989; 9: 934-939
  PubMedGoogle Scholar
• 33 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemostas 1989; 61: 370-373
  PubMedGoogle Scholar
• 34 Frade GLJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Avello GA. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-59
  CrossrefPubMedGoogle Scholar
• 35 Kokolis N, Ploumis Th, Smokovitis A. The effect of experimental chronic hypertension on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition. Thromb Res 1989; 56: 523-528
  CrossrefPubMedGoogle Scholar